New insights in the design of bioactive peptides and chelating agents for imaging and therapy in oncology

Research output: Contribution to journalReview articlepeer-review


Many synthetic peptides have been developed for diagnosis and therapy of human cancers based on their ability to target specific receptors on cancer cell surface or to penetrate the cell membrane. Chemical modifications of amino acid chains have significantly improved the biological activity, the stability and efficacy of peptide analogues currently employed as anticancer drugs or as molecular imaging tracers. The stability of somatostatin, integrins and bombesin analogues in the human body have been significantly increased by cyclization and/or insertion of non-natural amino acids in the peptide sequences. Moreover, the overall pharmacokinetic properties of such analogues and others (including cholecystokinin, vasoactive intestinal peptide and neurotensin analogues) have been improved by PEGylation and glycosylation. Furthermore, conjugation of those peptide analogues to new linkers and bifunctional chelators (such as AAZTA, TETA, TRAP, NOPO etc.), produced radiolabeled moieties with increased half life and higher binding affinity to the cognate receptors. This review describes the most important and recent chemical modifications introduced in the amino acid sequences as well as linkers and new bifunctional chelators which have significantly improved the specificity and sensitivity of peptides used in oncologic diagnosis and therapy.

Original languageEnglish
Article number1282
Issue number8
Publication statusPublished - Aug 1 2017


  • Chelators
  • Chemical modification
  • D-amino acids
  • DOTA
  • Glycosylation
  • NOPO
  • PEGylation
  • Peptide
  • Peptide cyclization
  • TETA
  • TRAP

ASJC Scopus subject areas

  • Medicine(all)
  • Organic Chemistry


Dive into the research topics of 'New insights in the design of bioactive peptides and chelating agents for imaging and therapy in oncology'. Together they form a unique fingerprint.

Cite this